Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Nordic Nanovector ASA. (5/4/16). "Press Release: Nordic Nanovector to Present at BioEquity Europe on 11 May 2016". Oslo.

Region Region København (Copenhagen)
  Country Denmark
Organisations Organisation Nordic Nanovector ASA (OSE: NANO)
  Group Nordic Nanovector (Group)
  Organisation 2 Citigate Dewe Rogerson Ltd.
  Group Huntsworth (Group)
Products Product BioEquity Europe 2016 Copenhagen
  Product 2 Betalutin®
Index term Index term Nordic Nanovector–Informa: partnering conference
Persons Person Costa, Luigi (Nordic Nanovector 201409– CEO before Onyx Pharmaceuticals + Amgen)
  Person 2 Swallow, Mark (Huntsworth 201101 Citigate Dewe Rogerson London)
     


Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology announces that Luigi Costa, Chief Executive Officer, will hold presentation at BioEquity Europe in Copenhagen, Denmark on Wednesday 11 May 2016.

The presentation will be available on the same day at Nordic Nanovector’s website (www.nordicnanovector.com, Investor Relations/Reports and Presentations/Presentations/2016).


###


For further information, please contact:

Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

International Media Enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk


About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com

Press Release 20/2016.

   
Record changed: 2017-07-02

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Nordic Nanovector (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px




» top